Dr. Blakely is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5653 Frist Blvd
Suite 434
Hermitage, TN 37076Phone+1 615-871-9996Fax+1 615-871-9661
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2001 - 2004
- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1999 - 2001
- University of TennesseeInternship, Internal Medicine, 1998 - 1999
- University of Tennessee Health Science Center College of MedicineClass of 1998
Certifications & Licensure
- TN State Medical License 2004 - 2026
- AR State Medical License 2004 - 2011
- TX State Medical License 2001 - 2007
- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2009-2012
- Top MD Consumers Checkbook
Clinical Trials
- Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
Publications & Presentations
PubMed
- 5 citationsRegorafenib Prior to Selective Internal Radiation Therapy Using 90Y-Resin Microspheres for Refractory Metastatic Colorectal Cancer Liver Metastases: Analysis of Safety...Andrew S. Kennedy, Dianna Shipley, Max Shpak, Laura Blakely, Brian Hemphill
Frontiers in Oncology. 2019-07-10 - 7 citationsA Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal ...Johanna C. Bendell, Mathew John Joseph, Kirk Barnes, Mark Mainwaring, Dianna Shipley
Cancer Investigation. 2017-04-20 - 6 citationsA Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast CancerDenise A. Yardley, William Liggett, Mark Mainwaring, Aurelio Castrellon, Laura Blakely
Clinical Breast Cancer. 2020-04-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: